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A deactivated alkene precursor (IC50 = 81 µM) to the 
azinomycin epoxide natural product can be bioactivated by 
several cytochromes P450 (CYP) to generate antiproliferative 
metabolites with increased potency (IC50 = 1-30 µM) in 
CHOwt cells. CYP1A1 and 3A4 were shown to generate 
exclusively the unnatural and the natural-configured 
azinomycin epoxide diastereoisomer respectively, while 
CYP1B1 produced both epoxides in a 3:1 mixture. The 
antiproliferative activity is linked to DNA damage as 
demonstrated using the comet assay. 
The azinomycins A (1), B (2) and the azinomycin epoxide (3) are 
natural products isolated from Streptomyces griseofuscus (strain 
S42227) that have been extensively studied due to their potent 
antitumour activity, their novel structures and their mode of action.1-
4 The complete azinomycin A and B structures 1 and 2 bind to the 
major groove of DNA and form interstrand crosslinks through 
alkylation by the epoxide and aziridine moieties.5, 6 The truncated 
epoxide structure 3 has been shown to alkylate at the N7 of guanine 
and promote a depurination reaction that leads to single strand 
breaks.7 The naphthalene moiety is important in 3 due to an ability to 
intercalate into the DNA duplex following alkylation.8  
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Figure 1. Structure of azinomycins A (1) and B (2) and the azinomycin 
epoxide (3).  
 
Although the azinomycins possess potent cytotoxicity in vitro, they 
have variable in vivo activity, most likely as a consequence of the 
metabolic instability of the epoxide and aziridine moieties. In studies 
to define the biosynthetic pathways to the azinomycins, Watanabe 
and co-workers have demonstrated that valine is the precursor to the 
epoxide.9 This amino acid undergoes a series of transformations to 
generate 3-methyl-2-oxobutenoic acid, which is predicted to be 
reduced to the alcohol and incorporated into the azinomycin 
structure.  Enzymatic epoxidation of the alkene amide also occurs in 
this sequence of events. This incorporation of an alkene is similar to 
the synthetic sequence described previously and adapted by us to 
generate all four diastereoisomers of 3.7 We hypothesised that the 
alkene derivative has utility as a bioprecursor that could increase the 
therapeutic utility of the azinomycins in malignant tissues that 
(over)express enzymes capable of epoxidising xenobiotics notably 
the cytochrome P450 (CYP) monoxygenases. Several drug 
metabolising CYPs have been shown to be expressed at high 
frequency in cancer tissues10 and we have focused our attention on 
several CYP1 and 2 family members as tumour selective prodrug 
activating enzymes. We developed AQ4N, a Phase II clinical trial 
candidate, to undergo bioreductive activation by CYP1A1 and 3A4 
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selectively in hypoxic tumours.11, 12 More recently we demonstrated 
that bioprecursors of the duocarmycins can be activated selectively 
to ultrapotent anti-proliferative metabolites by tumours expressing 
CYP1A113 and 2W114 and we are proposing this approach to address 
the failure of the duocarmycins in the clinic due to unacceptable 
normal tissue toxicity. Similarly, despite the promise of the 
azinomycins as cancer chemotherapeutics, they have thus far failed 
to progress clinically.   
Towards the aim of developing a class of chemotherapeutics 
based on the azinomycins we describe the synthesis and biological 
evaluation of a library of azinomycin epoxide bioprecursors with 
potential for CYP bioactivation   
We previously7 adopted the stereoselective synthesis of the 
epoxide 4 using Shipman’s methodology (i.e. a Sharpless 
dihydroxylation) in order to set the stereochemistry of the 
subsequent alkene (in this case, compound 6). In this study, we 
reasoned that as a proof-of-concept, synthesis of the racemic alkene 
is appropriate, as it is not predictable as to whether the 
stereochemistry of the naphthoate ester amide fragment has an 
influence on enzymic oxidation of the alkene by selected CYPs. The 
benzyl ester of commercially available 3,3-dimethylacrylic acid was 
epoxidised directly using m-CPBA to give an excellent yield (93%) 
of the racemic compound, a reaction which can be carried out on a 
multigram scale. Acid catalysed ring opening to give the alkene was 
followed by direct treatment with ammonia to give the amide 6.  
It has previously been shown that changes in substitution on the 
naphthalene ring maintain antitumour activity.15 In this study we 
wanted to establish whether the substitution pattern influenced CYP 
mediated epoxidation of the alkene. To facilitate this structure 
activity relationship (SAR) for CYP-catalysed epoxidation, we 
introduced a number of different analogues of the naphthalene 
moiety alongside the natural product structure. The aromatic 
substituents were introduced via DCC mediated coupling with 
fragment 6. Subsequent chemical oxidation of the alkenes gave a 
mixture of diastereoisomers that were separable into the racemic 
mixtures. The relative stereochemistry was assigned through 
reference to the H2 proton (-proton) in the 1H NMR which was 
shifted upfield (5.32 from 5.21 ppm) in the configuration opposite to 
that found in the natural azinomycin analogue.  
To determine the cytotoxicity of the truncated azinomycin 
precursors, chemosensitivity studies were carried out using a 
Chinese Hamster Ovary (CHO) cell line +/- transfected with 
CYP1A1. The anti-proliferative activity of the various naphthalene 
derivatives against this isogenic pair of CHO cell lines was assessed 
using the MTT cell viability assay (Table 1). The substitution pattern 
of the naphthalene moiety in the epoxyamide compounds 3 and 4 has 
little effect on the biological activity, with IC50 values between 2-10 
µM for all compounds tested. However, incubation of the alkenes 
5a-e with the cell lines demonstrated that only the natural product 
naphthalene structure (5a) was bioactivated in the CYP1A1 
expressing cell line, indicating that the substitution pattern on the 
naphthalene moiety affects the binding mode with CYP1A1. 
 
 
Table 1. Antiproliferative activity of azinomycin analogues in wild-
type and CYP1A1-transfected CHO cell lines 
 
 
Compound 
ID 
Structure of R group IC50 CHO 
(µM) 
IC50 CHO(1A1) 
(µM) 
3a  
 
2.8 3.2 
4a  5.7 6.0 
5a  85 6.3 
3b 
 
10 5 
4b 10 9 
5b >100 >100 
3c 
 
7 3 
4c 7 2 
5c >100 >100 
3d 
 
6 3 
4d 3 9 
5d >100 >100 
3e 
 
6 3 
4e 5 9 
5e >100 >100 
 
 
Scheme 1. Synthesis of compounds 3-6 
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Table 2. Growth inhibition of bioprecursor 5a and CYP bactosomes generated metabolite fractions of 5a against CHO cell line 
  
 *IC50 = µM; **Potentiation Factor (IC50 of 5a in CHO cells/IC50 of 5a + CYP isoform metabolites) 
 
 
Since the naphthoate substitution pattern of compound 5a is that 
of the natural azinomycin we explored whether other CYPs 
important in drug metabolism could influence its cytotoxicity. 
Bioactivation by CYP1A1 was compared to CYP1B1, known to be 
overexpressed in many tumour types16 and three hepatic CYPs 
(1A2, 2D6 and 3A4). NADPH dependent CYP/CYP reductase 
expressing bactosomes were incubated for 1 h with 5a. 
Subsequently the incubation extract was added to CHO wild type 
cells which were subjected to the MTT antiproliferative assay. This 
revealed that all CYPs could significantly (3-24 fold) potentiate 5a 
activity. Potentiation by CYP3A4 (24.4-fold) was much greater 
than CYP1B1 (7-fold) or CYP1A1 (5.8-fold), Table 2. The 
bioactivation of the CYP bactosomes brings the potency of the 
inactive azinomycin precursor to the low micromolar region, which 
is similar to what we have observed for the four diastereoisomers of 
compound 3 in the NCI 60 cell line panel.7 The CYP-mediated 
potentiation observed here suggests the possible formation of an 
azinomycin epoxide metabolite capable of causing DNA damage. 
We therefore explored the nature of this activation further.  
To investigate if the antiproliferative activity could be correlated 
with DNA damage, CHO cells were treated with bioprecursor 5a or 
the metabolite fraction generated from 5a incubation with the 
CYP3A4 bactosomes. After 1 h exposure to cells, DNA damage 
was assessed using the comet assay. EO9, camptothecin and 
melphalan were used as positive controls for DNA single strand 
breaks (SSBs), DNA double strand breaks (DSBs) and DNA 
interstrand cross-links (ICLs), respectively. The results showed that 
CYP3A4-generated metabolites were capable of producing DNA 
damage primarily through SSBs (Figure 2) with no evidence of 
DSBs as measured by increase in mean tail moment (MTM) (Figure 
S3). 
The results also indicated that a small amount of ICLs were 
generated. This is intriguing because it would require two sites of 
metabolic activation to generate the requisite proximate crosslinking 
alkylation sites. Furthermore, 5a alone produced no DNA damage 
confirming that CYP-activation is required for the generation of 
DNA damage. 
CYP2W1 has been reported to be expressed in both primary17 and 
metastatic18 colon cancer tissue but not healthy tissues and we are 
engaged with discovering new pharmacophores that are bioactivated 
by CYP2W1. In this context, we explored the potential for 5a to be 
bioactivated by CYP2W1 using our isogenic SW480 +/- CYP2W1 
cell line pair, but we did not observe any significant antiproliferative 
activity in the CYP2W1-transfected cells (Figure S4). However, 5a 
displayed a dose-dependent growth inhibition against two human 
gastric cancer cell lines, SGC-7901 and MKN-45, which expressed 
CYP1A1 and 3A4 at both gene and protein level (Figure 3).  
 
 
 
 
 
 
 
Figure 2. DNA damage caused by 5a metabolite generated from incubation 
with CYP3A4. DSBs and SSBs were measured by increase in MTM (A) and 
ICLs by a decrease in MTM (B). Typical comet images show SSBs with no 
drug (C), 20 µM E09 (D), 50 µM 5a (E) and 50 µM CYP3A4-metabolised 5a 
(F). DNA ICLs with no drug (G), 20 µM melphalan (H), 50 µM 5a (I) and 50 
µM CYP3A4-metabolised 5a (J). The results are the mean ± SD of at least 
three independent assays. 
 
 
Figure 3. CYP1A1 and 3A4 expression and antiproliferative activity in 
gastric cell lines SGC-7901 and MKN-45. CYP1A1 and 3A4 expression was 
measured by qRT-PCR (A) and Western blot (B). The growth inhibition was 
measured using the MTT assay (C).  
5a 5a + CYP1A1 5a + CYP1A2 5a + CYP1B1 5a + CYP2D6 5a + CYP3A4 
IC50*
 IC50 PF** IC50 PF** IC50 PF** IC50 PF** IC50 PF** 
81.61 ± 4.23 14.15 ± 3.07 5.8 20.30 ± 4.0 11.75 ± 7.0 28.31 ± 2.9 3.34 ± 24.4 
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To identify the active metabolites likely to be responsible for the 
DNA damage and CYP-associated antiproliferative activity, 
metabolite fractions from CYP1A1, 1B1 and 3A4 were analysed by 
LC/MS/MS. All three CYPs oxidised the alkene to the epoxide, the 
anticipated alkylating species of these truncated azinomycins. 
However the epoxide stereochemistry generated by different CYP 
isoforms was not the same. CYP1A1 and 3A4 were shown to 
generate exclusively the ‘unnatural’ diastereoisomer epoxide 3a and 
the naturally-configured epoxide 4a respectively, while CYP1B1 
produced both epoxides in a 3:1 mixture as identified by co-elution 
with the respective authentic truncated azinomycins (Figure 3). The 
IC50 data and our CYP-metabolism data from this study are 
consistent with the high potency of the naturally-configured 
diastereoisomer epoxides previously observed.7 
 
 
Figure 3. Metabolism profile of 5a incubated with CYP1A1, 1B1 or 3A4  
 
 
The identification of a m/z 330 metabolite, consistent with 
epoxide formation (Scheme 2), and DNA SSBs following CYP-
oxidation indicates the potential for bioactivation of the precursor 
azinomycins prepared in this study.  
 
Scheme 2. Generation of metabolites by CYP1A1, 1B1 and 3A4. 
 
 
 
 
Conclusions 
 
We have demonstrated that the putative bioprecursor 5a to the 
natural azinomycin product 3 can be activated in cells expressing a 
number of CYPs known to be responsible for drug metabolism. 
Certain isoforms, notably CYP1A1, 1B1 and 3A4 are identified as 
highly expressed in certain tumours10 indicating the value of 
truncated azinomycin analogues as potential bioprecursors with 
chemotherapeutic efficacy. We have demonstrated proof of principle 
with bioprecursors of the duocarmycin natural products targeting 
CYP1A119, 20 and 2W114, 21 enzymes. Uniquely, we have 
demonstrated that CYP selective bioactivation in vivo can be 
obtained with no overt toxicity to normal tissues including the 
liver.13, 14 Further development of such a bioprecursor approach 
could provide a strategy to exploit the azinomycins for therapeutic 
use. While CYP1A1 and 1B1 provide selective cancer drug targets, 
the hepatic CYP3A4 enzyme could be exploited for liver specific 
treatment of hepatitis B, hepatitis C and hepatocellular carcinoma22 
or with the reemergence of the oncolytic virus, a ‘suicide’ GDEPT 
approach also exists as a therapeutic strategy.23, 24 
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